- JP-listed companies
- SAPPORO CLINICAL LABORATORY INC.
- Balance sheet
SAPPORO CLINICAL LABORATORY INC.JP:9776
Market cap
¥8.3B
P/E ratio
12.2x
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Cash and cash equivalents | - | 2,664 | 3,068 | 3,135 | 4,057 | 4,478 | 2,728 | 2,361 | 2,991 | 3,664 | 3,976 | 2,941 |
| Total cash & short-term investments | - | 2,664 | 3,068 | 3,135 | 4,057 | 4,478 | 2,728 | 2,361 | 2,991 | 3,664 | 3,976 | 2,941 |
| Accounts receivable, net | - | 2,940 | 2,862 | 2,725 | 2,767 | 2,652 | 2,608 | 2,779 | - | - | - | - |
| Inventories | - | 533 | 447 | 523 | 465 | 525 | 452 | 433 | 410 | 432 | 501 | 531 |
| Total current assets | - | 6,317 | 6,561 | 6,611 | 7,489 | 7,762 | 5,932 | 5,913 | 7,230 | 7,311 | 7,697 | 6,636 |
| Property, plant and equipment, net | - | 2,023 | 2,202 | 2,344 | 2,379 | 2,109 | 4,865 | 7,758 | 8,128 | 8,449 | 8,191 | 8,906 |
| Marketable securities, non-current | - | 152 | 115 | 137 | 133 | 165 | 134 | 177 | 142 | 150 | 210 | 235 |
| Total non-current assets | - | 2,848 | 2,985 | 3,116 | 3,102 | 2,915 | 5,621 | 8,599 | 8,920 | 9,210 | 8,984 | 9,815 |
| Total assets | - | 9,165 | 9,546 | 9,728 | 10,591 | 10,678 | 11,553 | 14,511 | 16,149 | 16,521 | 16,681 | 16,451 |
| Accounts payable | - | 2,382 | 2,187 | 2,041 | 2,067 | 1,865 | 2,169 | 2,294 | 2,259 | 2,179 | 2,236 | 2,154 |
| Short-term debt | - | 25 | 22 | 13 | - | - | - | - | - | - | - | - |
| Long-term debt, current | - | 20 | 20 | 13 | - | - | - | 134 | 134 | 134 | 135 | 134 |
| Total current liabilities | - | 2,905 | 2,799 | 2,488 | 2,729 | 2,431 | 2,796 | 3,106 | 3,282 | 3,257 | 3,307 | 3,121 |
| Long-term debt, non-current | - | 35 | 13 | - | - | - | - | 1,866 | 1,732 | 1,599 | 1,465 | 1,331 |
| Total non-current liabilities | - | 298 | 263 | 255 | 265 | 265 | 294 | 2,133 | 2,530 | 2,384 | 2,191 | 1,936 |
| Total liabilities | - | 3,204 | 3,062 | 2,744 | 2,994 | 2,696 | 3,090 | 5,239 | 5,811 | 5,640 | 5,498 | 5,057 |
| Common stock and paid-in capital | - | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 | 1,999 |
| Retained earnings | - | 4,435 | 4,984 | 5,459 | 6,110 | 6,595 | 7,089 | 7,849 | 8,813 | 9,304 | 9,608 | 9,995 |
| Stockholders' equity | 5,825 | 5,961 | 6,484 | 6,984 | 7,597 | 7,981 | 8,463 | 9,272 | 10,337 | 10,880 | 11,183 | 11,394 |
| Total debt | - | 81 | 55 | 27 | - | - | - | 2,000 | 1,866 | 1,732 | 1,600 | 1,465 |
| Net debt | - | -2,584 | -3,013 | -3,108 | - | - | - | -361 | -1,125 | -1,932 | -2,376 | -1,476 |
| D/E ratio (%) | - | 1.4 | 0.9 | 0.4 | - | - | - | 21.6 | 18.1 | 15.9 | 14.3 | 12.9 |
| Working capital | - | - | - | - | - |